Ketamine-assisted therapy at luxury rehab

Something is finally working, and it still isn’t the whole plan

Ketamine sessions tend to follow a quiet pattern: a clinician in the room, a low dose, forty-five minutes to an hour of altered awareness, and a therapy session afterward to make sense of what surfaced. People who have spent years cycling through antidepressants with no real relief sometimes feel a shift within days.

That fast response is real, and it is also easy to overstate. Ketamine is a medication with a specific, narrow FDA approval, a longer off-label history, and a role that works best alongside ongoing therapy, not in place of it. Here is what the research actually supports, and what it does not yet.

What is ketamine-assisted therapy?

Ketamine-assisted therapy pairs a ketamine dose, given intravenously, intramuscularly, or as a nasal spray, with structured psychotherapy before and after the dosing session. At sub-anesthetic doses, ketamine can loosen rigid thought patterns for a few hours, and clinicians use that window to do therapeutic work that might otherwise take much longer to reach.

McLean Hospital, the Harvard-affiliated psychiatric hospital, offers both forms through its Ketamine Service: FDA-approved intranasal esketamine (Spravato) and off-label intravenous ketamine, for adults with major depressive disorder and bipolar depression.² The two are related but not identical, and the difference matters.

Is it FDA-approved?

Partly. Esketamine, sold under the brand name Spravato, is the S-enantiomer of ketamine, and it received FDA approval on March 5, 2019, for treatment-resistant depression in adults, used alongside an oral antidepressant.¹ Because of the risk of sedation, dissociation, and misuse, it is dispensed only in certified healthcare settings, where a clinician monitors the patient for at least two hours after each dose.¹

Ketamine itself, the generic compound given by IV or IM injection, has never gone through that FDA approval process for any psychiatric use. The National Institute on Drug Abuse is direct about this: “Although ketamine itself is not FDA-approved for any mental health disorder, dozens of clinics across the United States offer it off-label” for depression, anxiety, and other conditions.³ Off-label use means a licensed physician is applying clinical judgment to prescribe an approved drug for a use the FDA has not formally reviewed and cleared, a common and legal practice in psychiatry.

Does it treat addiction?

Not by FDA approval, and not on its own. NIDA states plainly: “Ketamine is not currently approved by FDA for the treatment of any substance use disorder.”³The agency is funding research into ketamine-assisted therapy for cocaine and methamphetamine addiction, and NIDA notes ketamine “is being investigated as a potential treatment for alcohol use disorder and other substance use disorders, such as opioid and cocaine use disorder.”³

A 2018 systematic review in Frontiers in Psychiatry looked at the available trials and found early signals worth taking seriously: across studies of cocaine, alcohol, and opioid use disorder, ketamine appeared to help some people stay abstinent longer, especially when combined with psychotherapy.⁴The same review was careful about the limits of that evidence: small sample sizes, short follow-up periods, and comparison groups that used low-dose ketamine rather than a true placebo. The authors’ conclusion was measured: ketamine “may facilitate abstinence across multiple substances of abuse and warrants broader investigation,” not that it is a proven treatment.⁴

In practice, this positions ketamine-assisted therapy as one tool inside a broader plan for someone with co-occurring depression, PTSD, or anxiety alongside substance use. The detox, structured therapy, and step-down care that treat the addiction itself remain the foundation, and ketamine sits alongside them when a psychiatrist judges it appropriate. If you are weighing whether it fits your situation, our guide to dual diagnosis care covers how co-occurring conditions are treated together.

Is it safe?

Under medical supervision, yes, with real caveats. Ketamine can raise blood pressure and heart rate, and it causes short-term dissociation, sometimes disorienting, which is precisely why esketamine’s REMS program requires two hours of monitoring after each dose.¹Longer-term or unsupervised use carries different risks: NIDA’s research points to bladder and urinary tract damage with heavy, repeated use, along with the potential for cravings and withdrawal symptoms outside a clinical setting.³

The safety profile inside a monitored clinical setting, administered by a physician, dosed conservatively, with recovery time built in, is well established for short courses. What is still being studied is the durability of the benefit and the right protocol for people with substance use histories, since ketamine is itself a controlled substance with misuse potential.

What this looks like at a luxury program

A small number of residential programs have brought ketamine-assisted therapy in-house rather than referring guests out for it. All Points North, the mountain lodge program in Colorado’s Vail Valley, offers ketamine-assisted therapy alongside Deep TMS and standard residential treatment for co-occurring depression, trauma, and addiction. Paracelsus Recovery, the single-client program in Zurich, includes ketamine-assisted therapy among the advanced psychiatric options its full-time clinical team can draw on for treatment-resistant cases.

Both treat it as one option among several, prescribed when a psychiatric evaluation supports it, not as a default offered to every guest. If a program presents ketamine as a guaranteed fix rather than one tool a psychiatrist may recommend after evaluation, that is worth questioning directly.

Most luxury residential programs treat depression, PTSD, and dual diagnosis through well-run standard care alone, without ketamine in the toolkit, and their outcomes reflect that. A program’s fit depends far more on its clinical team, its structure, and how it treats the whole picture than on whether ketamine-assisted therapy is available. To see which programs treat depression and co-occurring conditions, and how, visit our guide to depression treatment or find a center that matches your situation.